Research ExplorerPublicationsBenefit evaluation in multiple sclerosis relapse treatment f...

Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire

Standard

Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire. / Beckmann, Helen; Augustin, Matthias; Heesen, Christoph; Poettgen, Jana; Blome, Christine.

In: MULT SCLER RELAT DIS, Vol. 28, 02.2019, p. 256-261.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Beckmann, H, Augustin, M, Heesen, C, Poettgen, J & Blome, C 2019, 'Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire', MULT SCLER RELAT DIS, vol. 28, pp. 256-261. https://doi.org/10.1016/j.msard.2018.12.021

APA

Beckmann, H., Augustin, M., Heesen, C., Poettgen, J., & Blome, C. (2019). Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire. MULT SCLER RELAT DIS, 28, 256-261. https://doi.org/10.1016/j.msard.2018.12.021

Vancouver

Beckmann H, Augustin M, Heesen C, Poettgen J, Blome C. Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire. MULT SCLER RELAT DIS. 2019 Feb;28:256-261. https://doi.org/10.1016/j.msard.2018.12.021

Bibtex

@article{7a1617d44a9747f9b3ca8dc23b718fa4,
title = "Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire",
abstract = "BACKGROUND: Little is known on how to measure patient-relevant benefit of relapse treatment in relapsing-remitting multiple sclerosis (MS). The objective of this study was to develop and validate a new method for monitoring recovery from MS relapses and patient-relevant treatment benefits.METHODS: A 27-item questionnaire was developed using a multi-step approach comprising open item collection, multidisciplinary expert panel and cognitive debriefing. It was evaluated regarding psychometric properties and feasibility in a longitudinal validation study with 100 patients with MS undergoing relapse treatment. Construct validity was tested by correlations with patient and physician global impressions of change as well as disease-specific and generic health-related quality of life (HRQoL) measures.RESULTS: Results of the feasibility survey indicated high patient acceptance. Reliability was high (Cronbach's α = 0.90). While the Expanded Disability Status Scale (EDSS) was not sensitive to change, Patient Benefit Index for Multiple Sclerosis (PBI-MS) showed a high correlation cross-sectionally with patient global impression of change (PaGIC) (r = 0.60, p < 0.001). Significant moderate to high correlations were found with change in generic HRQoL (r = 0.55-0.61, p < 0.001) and lower correlations with change in disease-specific HRQoL (r = -0.36, p < 0.01).CONCLUSION: The PBI-MS is a reliable and valid instrument for ascertaining patient-relevant benefits of acute relapse treatment; it appears suited for use in routine care and in clinical or health care studies.",
keywords = "Journal Article",
author = "Helen Beckmann and Matthias Augustin and Christoph Heesen and Jana Poettgen and Christine Blome",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2019",
month = feb,
doi = "10.1016/j.msard.2018.12.021",
language = "English",
volume = "28",
pages = "256--261",
journal = "MULT SCLER RELAT DIS",
issn = "2211-0348",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire

AU - Beckmann, Helen

AU - Augustin, Matthias

AU - Heesen, Christoph

AU - Poettgen, Jana

AU - Blome, Christine

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: Little is known on how to measure patient-relevant benefit of relapse treatment in relapsing-remitting multiple sclerosis (MS). The objective of this study was to develop and validate a new method for monitoring recovery from MS relapses and patient-relevant treatment benefits.METHODS: A 27-item questionnaire was developed using a multi-step approach comprising open item collection, multidisciplinary expert panel and cognitive debriefing. It was evaluated regarding psychometric properties and feasibility in a longitudinal validation study with 100 patients with MS undergoing relapse treatment. Construct validity was tested by correlations with patient and physician global impressions of change as well as disease-specific and generic health-related quality of life (HRQoL) measures.RESULTS: Results of the feasibility survey indicated high patient acceptance. Reliability was high (Cronbach's α = 0.90). While the Expanded Disability Status Scale (EDSS) was not sensitive to change, Patient Benefit Index for Multiple Sclerosis (PBI-MS) showed a high correlation cross-sectionally with patient global impression of change (PaGIC) (r = 0.60, p < 0.001). Significant moderate to high correlations were found with change in generic HRQoL (r = 0.55-0.61, p < 0.001) and lower correlations with change in disease-specific HRQoL (r = -0.36, p < 0.01).CONCLUSION: The PBI-MS is a reliable and valid instrument for ascertaining patient-relevant benefits of acute relapse treatment; it appears suited for use in routine care and in clinical or health care studies.

AB - BACKGROUND: Little is known on how to measure patient-relevant benefit of relapse treatment in relapsing-remitting multiple sclerosis (MS). The objective of this study was to develop and validate a new method for monitoring recovery from MS relapses and patient-relevant treatment benefits.METHODS: A 27-item questionnaire was developed using a multi-step approach comprising open item collection, multidisciplinary expert panel and cognitive debriefing. It was evaluated regarding psychometric properties and feasibility in a longitudinal validation study with 100 patients with MS undergoing relapse treatment. Construct validity was tested by correlations with patient and physician global impressions of change as well as disease-specific and generic health-related quality of life (HRQoL) measures.RESULTS: Results of the feasibility survey indicated high patient acceptance. Reliability was high (Cronbach's α = 0.90). While the Expanded Disability Status Scale (EDSS) was not sensitive to change, Patient Benefit Index for Multiple Sclerosis (PBI-MS) showed a high correlation cross-sectionally with patient global impression of change (PaGIC) (r = 0.60, p < 0.001). Significant moderate to high correlations were found with change in generic HRQoL (r = 0.55-0.61, p < 0.001) and lower correlations with change in disease-specific HRQoL (r = -0.36, p < 0.01).CONCLUSION: The PBI-MS is a reliable and valid instrument for ascertaining patient-relevant benefits of acute relapse treatment; it appears suited for use in routine care and in clinical or health care studies.

KW - Journal Article

U2 - 10.1016/j.msard.2018.12.021

DO - 10.1016/j.msard.2018.12.021

M3 - SCORING: Journal article

C2 - 30639826

VL - 28

SP - 256

EP - 261

JO - MULT SCLER RELAT DIS

JF - MULT SCLER RELAT DIS

SN - 2211-0348

ER -